Page 66 - Contract Development News Today

/PRNewswire/ - Akanda Corp. ("Akanda") (NASDAQ: AKAN) and Tetra Bio-Pharma ("Tetra") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), today jointly announced that Akanda...

/PRNewswire/ -- In our ongoing mission to bolster business insight and further augment organic growth and acquisition strategies, Piramal Pharma Ltd (PPL)...

MUMBAI, India, July 7, 2022 /PRNewswire/ -- In our ongoing mission to bolster business insight and further augment organic growth and acquisition strategies, Piramal Pharma Ltd (PPL) today announced

/PRNewswire/ -- In our ongoing mission to bolster business insight and further augment organic growth and acquisition strategies, Piramal Pharma Ltd (PPL)...

SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- The global oral solid dosage contract manufacturing market size is expected to reach USD 54.7 billion by 2030, registering a CAGR of 6.0% over the

PARIS--(BUSINESS WIRE)--Regulatory News:EUROAPI (Paris:EAPI) announces that, ahead of the publication of its 2022 half-yearly financial report on September 1st, 2022, it has made available financial information relating to the first half of 2021, including its historical half-year income statement and restated half-...

/PRNewswire/ -- The "Pharmaceutical Contract Development & Manufacturing Market by Service, End User - Global Forecast to 2029" report has been added to...

Global CDMO honored for Growth in Mammalian, Microbial and Cell and Gene Manufacturing capabilities at Seattle, Boulder and Longmont sitesSEATTLE, June 29, 2022, a leading global Biopharmaceutical Contract

Global CDMO honored for Growth in Mammalian, Microbial and Cell and Gene Manufacturing capabilities at Seattle, Boulder and Longmont sites...

The EMA CHMP has recommended granting approval for AstraZeneca and Merck’s Lynparza (olaparib) for high-risk early breast cancer patients.